HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM

INmune Bio (NASDAQ: INMB) is a clinical-stage immunotherapy company with 3 drug programs focused on harnessing the innate immune system to treat cancers and neurodegenerative diseases initially focused on Alzheimer’s disease.

INmune Bio Inc. (NASDAQ: INMB) - a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.

3 Drug Programs in Clinical Trials:

What is the innate immune system?

Our body’s immune system is broken into two components, innate and adaptive. **Innate** is an immediate, non-specific, initial response, serving as a first line of defense against infection and cancer. **Adaptive** is a highly specific response to bacteria, virus or other microorganisms that causes disease. As a system, both the innate and adaptive immune system are required for effective therapy. Most drug development programs focus on the adaptive immune response and ignore innate immunity. INMB harnesses the innate immune system with a targeted biomarker approach.

INB03

- Targets Myeloid-Derived Suppressor Cells (MDSC) that can inhibit anti-tumor immune reactions and stimulate tumor growth
- Resistance to CPI* – fast growing oncology market segment

INKmune™

- Biologic therapy that primes NK cells to eliminate minimal residual disease – a major cause of cancer relapse and death
- First trials in women with relapsed/refractory ovarian cancer Residual disease

XPro1595

- Targeting microglial cells to decrease neuroinflammation – a cause of brain cell loss and dysfunction in Alzheimer’s disease
- Alzheimer’s disease/dementia market - 50 million people worldwide
- Awarded $1 million grant from Alzheimer’s Association

### Pipeline – Multiple Shots on Large Goals:

<table>
<thead>
<tr>
<th>Product</th>
<th>Geography</th>
<th>Indication</th>
<th>Event</th>
<th>Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>INB03</td>
<td>Australia</td>
<td>Solid Tumors</td>
<td>Initial Phase 1 Data Readout</td>
<td>Q3 ’19</td>
</tr>
<tr>
<td>INKmune</td>
<td>UK</td>
<td>Ovarian Cancer</td>
<td>Initiate Enrollment of Phase 1/2 study</td>
<td>Q4 ’19</td>
</tr>
<tr>
<td>INB03</td>
<td>Australia</td>
<td>Solid Tumors</td>
<td>Initiate Combination Study, Additional Cohorts to Phase 1 Study</td>
<td>1H ’20</td>
</tr>
<tr>
<td>XPro1595</td>
<td>UK</td>
<td>Alzheimer’s</td>
<td>Initiate Enrollment of Phase 1 Study</td>
<td>Q3’19</td>
</tr>
<tr>
<td>INKmune</td>
<td>UK</td>
<td>Ovarian Cancer</td>
<td>Report Initial Phase 1 Data</td>
<td>1H ’20</td>
</tr>
<tr>
<td>XPro1595</td>
<td>UK</td>
<td>Alzheimer’s</td>
<td>Early Data</td>
<td>Q1’20</td>
</tr>
<tr>
<td>INKmune</td>
<td>UK</td>
<td>Ovarian Cancer</td>
<td>Initiate Phase 2 Study</td>
<td>2H ’20</td>
</tr>
<tr>
<td>INB03</td>
<td>Australia/US</td>
<td>Solid Tumors</td>
<td>Initiate INB03 + CPI* Phase 2 Combination Study</td>
<td>1H ’20</td>
</tr>
</tbody>
</table>
INmune Bio Inc. (NASDAQ: INMB)
www.INmuneBio.com

Information about Forward-Looking Statements
This fact sheet may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the company’s filings with the SEC. The occurrence of any of these risks and uncertainties could have a material adverse effect on the company’s business, financial condition, and results of operations. For additional disclosure regarding risks faced by INmune Bio, Inc., please see our public filings with the Securities and Exchange Commission, available on the Investors section of our website at www.INmuneBio.com and on the SEC’s website at www.SEC.gov.

INBO3 Improves Checkpoint Inhibitor Function
MDSC “force field” before INBO3

Cancer killing T cell after CPI* can not kill cancer cells due to MDSC

Cancer cells live and grow

INBO3 Development Program
Ongoing Phase 1 Open-Label, Dose-Escalation Trial
12 patients with advanced solid tumors with biomarkers of chronic inflammation including increased MDSC
• Treatment: INBO3 sub-cutaneous once a week
• Endpoints: Safety and decreased MDSC

Phase 2 Trial in Stage IV Melanoma* + CPI
Patients resistant to CPI* with increased MDSC
• Treatment: Combination therapy INBO3 + CPI*
• Endpoints: Decreased MDSC and no resistance to CPI* with improved progression free/overall survival

*subject to modification pending results of Phase 1

Xpro1595: Neuroinflammation, the “Ignored” Element of Alzheimer’s Disease
Phase 1: Alzheimer’s Disease
Biomarker directed trial of patients with inflammation and proven Alzheimer’s diseases
18 patients in 3 cohorts
• Weekly XPro1595 subQ for 3 months
• Biomarkers of inflammation at 0, 6 and 12 weeks
• Endpoints:
  • Safety
  • Decreased inflammation blood, cerebrospinal fluid (CSF), brain and breath
  • Measures of cogitation, psychiatric symptoms and quality of life (QOL)

INKmune: Treat Minimal Residual Disease (MRD**)
Residual disease is the cancer that is left behind after treatment; two types – overt (visible by imaging studies) and minimal (MRD** – NOT visible by imaging studies)

NK cells are responsible for eliminating MRD**, problem is patient’s NK cells are inactive, however INKmune primes the NK cells to kill the cancer

Phase 1/2 study in relapsed/refractory CaOva
• Platinum resistant/refractory patients with minimal residual disease
• Treatment: INKmune - 6 doses
• Endpoints: Safety, increased NK activation and tumor killing and decreased tumor burden (when in Phase 2)

Experienced Leadership
Management
Raymond J. Tesi, MD – CEO, CMO, Chairman
David J. Moss – CFO
Professor Mark Lowdell, PhD – CSO/CMO

Directors
Raymond J. Tesi, MD (Chairman)
David Szymkowski, PhD (VP of Cell Biology, Xencor)
J. Kelly Ganji (CEO of Cognate)
Scott Juda (Founder and Managing Member, Fossick Capital)
Timothy Schroeder (CEO and Founder of CTI)

Financial Snapshot (as of June 14, 2019)
NASDAQ (closed IPO in February 2019): INMB
Share Price: $10.36
Market Cap: 107.6M
Shares Outstanding (common/ fully diluted, as of 5/10/19): 10.3M / 13.3M
Insider Ownership: 63.09%
Debt: $0
Analyst Coverage: Maxim (BUY, $13PT)

INBO3 Improves Checkpoint Inhibitor Function
MDSC “force field” after INBO3

Cancer killing T cell after CPI* kills cancer cells when MDSC is eliminated by INBO3

Cancer cells killed by CPI* powered T cells

INBO3 Improves Checkpoint Inhibitor Function
MDSC “force field” before INBO3

Cancer killing T cell after CPI* can not kill cancer cells due to MDSC

Cancer cells live and grow

INBO3 Development Program
Ongoing Phase 1 Open-Label, Dose-Escalation Trial
12 patients with advanced solid tumors with biomarkers of chronic inflammation including increased MDSC
• Treatment: INBO3 sub-cutaneous once a week
• Endpoints: Safety and decreased MDSC

Phase 2 Trial in Stage IV Melanoma* + CPI
Patients resistant to CPI* with increased MDSC
• Treatment: Combination therapy INBO3 + CPI*
• Endpoints: Decreased MDSC and no resistance to CPI* with improved progression free/overall survival

*subject to modification pending results of Phase 1

Xpro1595: Neuroinflammation, the “Ignored” Element of Alzheimer’s Disease
Phase 1: Alzheimer’s Disease
Biomarker directed trial of patients with inflammation and proven Alzheimer’s diseases
18 patients in 3 cohorts
• Weekly XPro1595 subQ for 3 months
• Biomarkers of inflammation at 0, 6 and 12 weeks
• Endpoints:
  • Safety
  • Decreased inflammation blood, cerebrospinal fluid (CSF), brain and breath
  • Measures of cogitation, psychiatric symptoms and quality of life (QOL)

INKmune: Treat Minimal Residual Disease (MRD**)
Residual disease is the cancer that is left behind after treatment; two types – overt (visible by imaging studies) and minimal (MRD** – NOT visible by imaging studies)

NK cells are responsible for eliminating MRD**, problem is patient’s NK cells are inactive, however INKmune primes the NK cells to kill the cancer

Phase 1/2 study in relapsed/refractory CaOva
• Platinum resistant/refractory patients with minimal residual disease
• Treatment: INKmune - 6 doses
• Endpoints: Safety, increased NK activation and tumor killing and decreased tumor burden (when in Phase 2)

Experienced Leadership
Management
Raymond J. Tesi, MD – CEO, CMO, Chairman
David J. Moss – CFO
Professor Mark Lowdell, PhD – CSO/CMO

Directors
Raymond J. Tesi, MD (Chairman)
David Szymkowski, PhD (VP of Cell Biology, Xencor)
J. Kelly Ganji (CEO of Cognate)
Scott Juda (Founder and Managing Member, Fossick Capital)
Timothy Schroeder (CEO and Founder of CTI)

Financial Snapshot (as of June 14, 2019)
NASDAQ (closed IPO in February 2019): INMB
Share Price: $10.36
Market Cap: 107.6M
Shares Outstanding (common/ fully diluted, as of 5/10/19): 10.3M / 13.3M
Insider Ownership: 63.09%
Debt: $0
Analyst Coverage: Maxim (BUY, $13PT)